Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.
B3 thymoma
Immunotherapy
PD-L1
Thymic carcinoma
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
07
2019
accepted:
01
11
2019
entrez:
13
12
2019
pubmed:
13
12
2019
medline:
13
12
2019
Statut:
epublish
Résumé
Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze cohort of TB3 and TC with a panel of antibodies to assess the prevalence of PD-L1 expression, its prognostic value and to set up a reproducible test. We retrospectively studied 103 patients samples of FFPE histologically confirmed TB3 ( TB3 epithelial cells had a higher and more diffuse expression of PD-L1 than TC regardless the antibodies tested ( Frequent PD-L1 expression, particularly in TB3, paves the way for immunotherapy in TET (Thymic Epithelial Tumor). Otherwise, we have set up three reproducible LDT (laboratory-developed test) for four PD-L1 antibodies.
Sections du résumé
BACKGROUND
BACKGROUND
Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze cohort of TB3 and TC with a panel of antibodies to assess the prevalence of PD-L1 expression, its prognostic value and to set up a reproducible test.
METHODS
METHODS
We retrospectively studied 103 patients samples of FFPE histologically confirmed TB3 (
RESULTS
RESULTS
TB3 epithelial cells had a higher and more diffuse expression of PD-L1 than TC regardless the antibodies tested (
CONCLUSION
CONCLUSIONS
Frequent PD-L1 expression, particularly in TB3, paves the way for immunotherapy in TET (Thymic Epithelial Tumor). Otherwise, we have set up three reproducible LDT (laboratory-developed test) for four PD-L1 antibodies.
Identifiants
pubmed: 31827799
doi: 10.1186/s40364-019-0177-8
pii: 177
pmc: PMC6894111
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Informations de copyright
© The Author(s). 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Clin Oncol. 2019 Aug 20;37(24):2162-2170
pubmed: 29906252
Oncotarget. 2013 Jun;4(6):890-8
pubmed: 23765114
J Thorac Oncol. 2015 Oct;10(10):1383-95
pubmed: 26295375
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Expert Rev Anticancer Ther. 2012 May;12(5):685-95
pubmed: 22594902
Lung Cancer. 2018 Nov;125:35-42
pubmed: 30429036
J Thorac Oncol. 2009 Oct;4(10):1270-3
pubmed: 20197733
Lancet Oncol. 2018 Mar;19(3):347-355
pubmed: 29395863
Thorac Cancer. 2018 Nov;9(11):1341-1353
pubmed: 30168897
Ann Thorac Surg. 2019 Feb;107(2):418-424
pubmed: 30312607
Ann Pathol. 2014 Feb;34(1):87-91
pubmed: 24630641
Cancer Res. 2003 Jul 1;63(13):3708-15
pubmed: 12839963
Lung Cancer. 2016 Jul;97:99-104
pubmed: 27237035
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Hum Pathol. 2017 Feb;60:16-23
pubmed: 27746267
J Thorac Oncol. 2014 Dec;9(12):1737-9
pubmed: 25393790
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Thorac Oncol. 2014 May;9(5):596-611
pubmed: 24722150
Mod Pathol. 2017 Jun;30(6):826-833
pubmed: 28281549
J Thorac Oncol. 2015 Mar;10(3):500-8
pubmed: 25402569
Ther Adv Respir Dis. 2015 Jun;9(3):105-20
pubmed: 25827132
BMC Immunol. 2019 Jan 11;20(1):4
pubmed: 30634925
Ann Thorac Surg. 2016 Apr;101(4):1361-9
pubmed: 26794891
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Sci Rep. 2019 Feb 20;9(1):2369
pubmed: 30787364
J Thorac Oncol. 2018 Aug;13(8):1204-1212
pubmed: 29702286
Lung Cancer. 2015 May;88(2):154-9
pubmed: 25799277